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BMC Research Notes recently published a research article regarding the use of ligated DNA extracted from
formalin-fixed paraffin embedded (FFPE) tissue on the Illumina Infinium methylation platform - “Interpretation of
genome-wide infinium methylation data from ligated DNA in formalin-fixed, paraffin-embedded paired tumor and
normal tissue” Jasmine et al. BMC Research Notes 2012, 5:117. This article repeatedly refers to our previous work
and concludes that methylation data obtained from ligated FFPE extracted DNA should be used with great caution.
In this Discussion we review the data analysis performed in Jasmine et al’s paper and suggest limitations which
subsequently lead the authors to draw what we believe are incorrect conclusions. Moreover, we continue to
analyse genome-wide methylation data from DNA extracted from FFPE tissue successfully on both the HumMeth27
and 450 K arrays.Discussion
We are writing in response to the recently published re-
search article “Interpretation of genome-wide infinium
methylation data from ligated DNA in formalin-fixed,
paraffin-embedded paired tumor and normal tissue”
Jasmine et al. BMC Research Notes 2012, 5:117 [1].
Throughout the article reference is made to our previ-
ously published paper describing a novel method for the
analysis of formalin-fixed, paraffin embedded (FFPE)
extracted DNA on the Illumina HumMeth27 DNA
methylation array [2]. We feel that there are at least four
major limitations concerning the statistical analysis
implemented in Jasmine et al’s paper, which lead to the
conclusions drawn to be overly pessimistic.Batch effects
One issue which Jasmine et al. acknowledge in their Dis-
cussion is that of a potential batch effect confounding
their analysis. This batch phenomenon has been described
in the analysis of HumMeth27 data by Teschendorff et al.* Correspondence: christina.thirlwell@ucl.ac.uk; a.teschendorff@ucl.ac.uk
Medical Genomics Laboratory, UCL Cancer Institute, 72, Huntley Street,
London WC1E 6BT, UK
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reproduction in any medium, provided the or[3] and Leek JT et al. [4]. As pointed out in Leek JT et al.,
it is not uncommon that over 50 to 80% of measured
probes may be subject to confounding by batch effects. In
Jasmine’s paper, all of the fresh frozen (FF) samples were
analysed on a separate date/batch to the FFPE samples,
hence it is not entirely surprising that the largest variation
is associated with batch, and that consequently the corre-
lations between the matched FF and FFPE samples is
lower than expected. Moreover, since batch and FF/FFPE
status are completely confounded (in our view a funda-
mental limitation of their study), it is simply wrong to
draw the conclusion that the differences seen are entirely
driven by FF/FFPE status.Differentially methylated loci (DML) analysis
Jasmine et al. imply that among the top 50 DMLs from
the FFs and FFPEs there are “only” 7 in common. This is
without determining whether 7 is significant or not. In
fact, a simple binomial test shows that 7 is greater than
would be expected by random chance: under the null,
the expected number of overlaps would be approximately
50*(50/27000) = ~0.1+/−0.6, that is, on average we would
expect no CpGs to overlap among the corresponding topl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lap of 7 is P < 1 × 10-10, i.e this is highly significant. In our
experience, that among the top 50, there are 7 loci that
overlap (i.e a 14% (7/50) overlap), reflects a relatively
strong agreement exactly in line with the fact that the FF
and FFPE samples were derived from the same patients
and given that they were only comparing 12 samples in
each phenotype. Therefore, that the overlap is not stron-
ger (i.e over 50%) is simply down to a lack of power. This
should not be surprising since as shown in Ein-Dor et al.
[5], the ranking of features in “omic” studies becomes
stable (i.e over 50% overlap) only when relatively many
samples are analysed (>100 samples).
Data analysis methodology for calling DML’s
The overlap of DMLs between the FF and FFPE sets
might be even larger if the authors had used a Bayesian
state of the art algorithm for detecting DMLs. In fact,
Jasmine et al. used the Illumina in-house model for call-
ing and ranking DMLs, which estimates variance from
an in-house (and therefore independent) experiment.
Hence, the variance/noise estimates used by the authors
do not reflect the variance/noise estimates of their own
data, a key point which will definitely have affected the
ranking of the DMLs. Given that the authors were only
comparing 12 versus 12 samples, it would be more ac-
curate to have called and ranked DMLs according to a
Bayesian framework with locus-specific variances esti-
mated from the data itself, as implemented for instance
in the limma R package [6].
Concordance evaluation
Generating scatterplots of –log10 (p-values) between the
FF and FFPE sets is inadequate for evaluating concord-
ance. P-values are highly unstable and don’t reflect the
directionality of methylation changes. Jasmine et al.
should have generated a scatterplot of the statistics of
differential methylation (e.g the regularized t-statistic for
DMLs (cancer minus normal)) for FFs against the corre-
sponding statistics obtained using FFPEs, all derived using
an empirical Bayes framework [5]. It is likely that this would
have revealed a strong agreement in terms of the broad
statistical significance and directionality (i.e. hyper/hypo
methylation) of DMLs.
We continue to successfully analyse FFPE extracted
DNA on the Illumina HumMeth platform and have
refined the original published method [2] which has
improved the performance of these samples (manuscript
in press). We have also tested the Illumina FFPE DNA
sample QC kit which has been developed specifically for
this assay and tested in-house methods alongside this.
In conclusion, we suggest that should Jasmine et al.
have analysed their data as set out above and designed
their experiment to eliminate/minimise batch effects,their findings would demonstrate the effective use of
DNA extracted from FFPE tissue on the Illumina Hum-
Meth platform.
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In our recently published paper [1], we have shown
genome-wide methylation data derived from modified
Infinium protocol using ligated FFPE DNA as was ori-
ginally shown by Thirlwell et al. [2]. It may be noted
that Thirlwell et al. [2] did not compare tumor and nor-
mal tissue to identify tumor specific DML from FF and
FFPE tissue. Our data suggested that the tumor specific
DML detected in FFPE samples are not quite the same
as the tumor-specific DML detected from FF tissue (gold
standard) from exactly the same patients. Based on our
findings we concluded that Infinium methylation data
from FFPE should be interpreted cautiously. We thank
Thirlwell et al. for their interest in our paper and com-
menting on the following issues:
Batch effect: We acknowledge that in the presence of
batch effect there is potential for finding some false tis-
sue specific DML (FF vs. FFPE). However, the fact that
all the FF samples from tumor and normal were ana-
lyzed in a single batch and paired samples were put on
same chip (same for FFPE samples) there should not be
any batch effect while detecting the tumor-specific
DML. Unfortunately, we found largely different sets of
tumor specific DML while using FF and FFPE samples.
It may be mentioned that in our experience Infinium
methylation assay is very reproducible and inter-batch
replicate (done in two different labs at different time)
gave us very strong correlation (r = 0.96 to 0.98) [7].
DML analysis: we have shown the actual numbers
and/or percentage of the overlapping tumor specific DML
derived from FF and FFPE samples. We agree that statisti-
cally speaking 7 loci out of top 50 DML (14% overlap)
being shared among the two lists is unlikely to be due to
chance, however we leave the importance of this overlap-
ping proportion to the readers and researchers who would
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looked at the performance of modified Infinium protocol
on FFPE samples for the usual suspects (frequently found
DML in tumor) - see Additional file 6: Table S2 in the ori-
ginal manuscript) [1]. Results were not satisfactory for
FFPE. Regarding sample size and power of the study, ana-
lysis of our own methylation data suggested that we had
>90% power to detect a 1.25 fold change between tumor
and normal groups (in other words a difference of methy-
lation beta value of 0.1 and 0.125 or between 0.5 and
0.625) both in FF and FFPE samples.
Methodology for calling DML: It may be noted that
Thirlwell et al. have somehow overlooked the fact that
we used multivariate ANOVA to detect the DML. We
also showed results from paired t-test and Bootstrapping
(see Additional file 3: Figure S3 of original paper) [1].
Therefore their comments regarding the variance/noise
estimates does not apply to our data analysis. We ac-
knowledge that we did not use Bayesian framework, but
all three statistical tests that were applied to identify
DML in our paper are pretty standard and statistically
appropriate for the type of research question and there
was substantial overlap between them (see AdditionalFigure 1 Scatterplot of t-statistics from paired t-test between tumor a
FF samples (x-axis) from the same patients.file 3: Figure S3 of original paper [1]) indicating that we
picked up the true DML [1]. Previously we also have
seen very good overlap between results from Illumina’s
DiffScore and results based on the multivariate ANOVA
[8] and therefore could not completely agree with their
criticism of DiffScore analysis. Vast majority of true
DML should survive any valid statistical tests applied to
the data [8].
Concordance: We agree with Thirlwell et al. that p-
value is often unstable. In fact we have tested the re-
search question from different angles. The scatterplot
from –log p-value was shown in additional material, but
in the main body we also showed the loci specific correl-
ation between FF and FFPE (see Figure six in the original
manuscript [1]) for all the 27 K loci [1]. In our data, we
could not see meaningful strong correlation. As per the
suggestion by Thirlwell et al., we have now added the
scatterplot of t-statistics from paired t-test between
tumor and normal in FFPE (y-axis) over FF (x-axis) in
Figure 1, which also does not show strong concordance
between FF and FFPE results. In the original paper we
went further to examine the effect of ligation on FFPE
DNA by testing the performance on SNP genotypingnd corresponding normal tissue from FFPE samples (y-axis) and
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formance was significantly poor than FF samples [1].
Performance of FFPE samples on DASL assay was also
not optimal [9]. Although somewhat pessimistic, our
words of caution for interpretation of genome-wide data
from Illumina Infinium platform are based on our
microarray data.
In fact we, like other cancer researchers, would be very
pleased if one could get identical biological information
regarding tumor specific DML or gene from widely
available FFPE samples as one would expect from FF
samples from same individuals. Unfortunately so far no
published paper has clearly demonstrated that. It would
have been better if Thirlwell et al. presented some real
data showing tumor specific DML from FF and FFPE
samples in their signed response.
Lastly, our entire data is submitted to GEO and will be
released in due course. So, researchers are welcome to
apply any statistical tests that they feel appropriate and
make their own conclusions. Recently Illumina has fur-
ther modified the assay by adding another step to restore
FFPE DNA before ligation step for methylation assay.
We are yet to evaluate that kit to investigate if FFPE
samples can provide similar information as FF samples.
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